D. Boral Capital Reiterates Buy Rating for Clene (NASDAQ:CLNN)

D. Boral Capital restated their buy rating on shares of Clene (NASDAQ:CLNN) in a research report report published on Tuesday morning,Benzinga reports. They currently have a $23.00 target price on the stock.

A number of other analysts have also recently weighed in on CLNN. HC Wainwright reaffirmed a “buy” rating and set a $31.00 target price on shares of Clene in a research note on Thursday, November 14th. Canaccord Genuity Group decreased their target price on shares of Clene from $86.00 to $83.00 and set a “buy” rating on the stock in a research note on Thursday, November 14th. Finally, Benchmark reduced their price objective on shares of Clene from $90.00 to $84.00 and set a “buy” rating on the stock in a research note on Friday, November 22nd. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $55.25.

Clene Stock Performance

NASDAQ CLNN opened at $4.27 on Tuesday. The firm’s fifty day moving average price is $4.81 and its two-hundred day moving average price is $5.05. The stock has a market cap of $35.55 million, a PE ratio of -0.81 and a beta of 0.24. Clene has a fifty-two week low of $3.82 and a fifty-two week high of $10.40.

Institutional Trading of Clene

Institutional investors have recently modified their holdings of the business. SBI Securities Co. Ltd. bought a new stake in shares of Clene in the fourth quarter worth $69,000. Fullcircle Wealth LLC acquired a new position in Clene in the fourth quarter valued at $69,000. Renaissance Technologies LLC acquired a new position in Clene in the fourth quarter valued at $96,000. Parsons Capital Management Inc. RI acquired a new position in Clene in the fourth quarter valued at $194,000. Finally, Geode Capital Management LLC lifted its holdings in Clene by 52.9% in the fourth quarter. Geode Capital Management LLC now owns 65,112 shares of the company’s stock valued at $346,000 after buying an additional 22,539 shares during the period. Institutional investors own 23.28% of the company’s stock.

About Clene

Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.